Angiotensin (Ang) II infusion increases atherosclerosis and leads to the formation of abdominal aortic aneurysms in apolipoprotein E-deficient (ApoEϪ/Ϫ) mice. Conversely, blockade of the renin-angiotensin system (RAS) decreases atherosclerosis in this model. However, there are conflicting data in the literature concerning responses to both Ang II infusion and RAS blockade which may depend on age, sex, dose, duration of treatment, and the site at which lesion area was measured. In the present study we examined the effects of Ang II infusion on lesion formation in male ApoEϪ/Ϫ mice both at the aortic sinus and in the descending aorta, starting at different ages, and varying in duration. We also tested the effects of the Ang II receptor antagonist losartan at different doses in both males and females. Blood pressure and plasma renin concentration (PRC) were measured as indicators of the hemodynamic and neurohormonal effects of these treatments. Administration of Ang II increased lesion area much more in the descending aorta than at the aortic sinus. However, spontaneous lesion development at the aortic sinus was much greater than in more distal regions of the aorta. Aneurysms were observed in all treatment groups but were less severe in animals treated from 4 weeks age, possibly because of protective remodeling. Losartan treatment reduced lesion area at the aortic sinus, although differences were only significant in female mice. These findings demonstrate regional and temporal differences in the sensitivity of the aorta to the effects of RAS stimulation and blockade, and may help to explain some of the discrepancies between previous reports from other laboratories. Am J Hypertens 2005;18:486 -492
A ngiotensin II (Ang II) can affect almost every step in the development of atherosclerosis. Ang II enhances the expression of cell surface adhesion molecules, chemokines, and cytokines [1] [2] [3] [4] [5] and stimulates the oxidation of plasma lipoproteins, 6 which increases lipoprotein uptake by macrophages and endothelial cells. 7, 8 Reactive oxygen species may also be involved in signal transduction from Ang II receptors to atherogenic mechanisms, 9 and may degrade the protective functions of the endothelium by reducing the availability of nitric oxide (NO). 6, 10, 11 In addition, Ang II can stimulate smooth muscle cell proliferation both in vitro [12] [13] [14] [15] and in vivo, 16 thus contributing to remodeling of the arterial wall and to the formation of the fibrous cap of advanced lesions. Angiotensin II can also promote thrombosis by stimulating both uPA 17 and tPA, 18 and by inhibiting plasminogen activator inhibitor-1 (PAI-1). 18, 19 Occlusion of coronary arteries by plaque rupture and thrombus formation is thought to be a major cause of myocardial infarction. 20 Several recent studies have shown that Ang II infusion greatly stimulates atherogenesis in ApoEϪ/Ϫ mice. 17, [21] [22] [23] [24] [25] Daugherty et al first reported increases in aortic atherosclerotic lesions and also observed a high frequency of aortic aneurysms in ApoEϪ/Ϫ mice treated with Ang II from 24 to 28 weeks age. 21 Similarly, Weiss et al 23 reported 12-and 20-fold increases in atherosclerotic lesion area in the abdominal aorta and 26-and 7-fold changes in the ascending aorta of mice fed a low-fat diet and infused with Ang II for 4 and 8 weeks; however, they reported no evidence of aortic aneurysm formation. Differences in the age at which treatment was started and duration of treatment may have played roles in determining the outcome of these studies. Conversely, several studies of RAS blockade in ApoE-deficient (ApoEϪ/Ϫ) mice have reported significant reductions in lesion area, 26 -28 whereas others found no effect 29, 30 unless another drug was added 29 or unless atherosclerosis was stimulated by inactivation of both ApoE and endothelial nitric oxide synthase (eNOS) genes. 30 In the present study, we examined the effect of beginning Ang II infusion at different ages and of maintaining the infusion for different periods of time, and we compared the effect on the development of atherosclerosis at the aortic sinus and in the descending aorta. We also tested the effects of angiotensin receptor blockade and quantitatively assessed the dose-response relationship of this blockade, through its effects on blood pressure (BP) and reactive increments in plasma renin concentration (PRC).
Methods
All procedures were approved by the Animal Care and Use Committee of the Weill Medical College, Cornell University. Mice that were ApoE-deficient and that had a C57BL/6 genetic background were purchased from Jackson Laboratories (Bar Harbor, ME). Angiotensin II (Peninsula Laboratories Inc., San Carlos, CA) was dissolved in saline and delivered via a 28-day Alzet minipump (model 2004, Durect Corp., Cupertino, CA) at a rate of 1000 ng/kg/min. Minipumps were replaced to deliver infusions for longer periods. Losartan (the generous gift of Dr. Samuel Wright, Merck Laboratories, Rahway, NJ) was dissolved in water to deliver doses of 5 and 25 mg/kg/day, assuming a drinking rate of 2 mL/day.
Blood was obtained by retro-orbital puncture, and BP was measured by tail-cuff plethysmography. 31 Plasma renin concentration was measured by incubating plasma with exogenous angiotensinogen and quantifying the Ang I generated by radioimmunoassay. 32 Measurements of lesion area at the aortic sinus and determinations of total and HDL cholesterol were made as previously described. 33 Lesion area in the descending aorta, from the branch point of the right cephalic artery to the iliac bifurcation, was measured after staining with Oil Red O and quantified by digital microscopy. Abdominal aortic aneurysms were graded according to the scale developed by Daughery et al, 22 as follows: 0 ϭ no aneurysm, 1 ϭ dilated lumen in the suprarenal aorta with no thrombus, 2 ϭ remodeled tissue in the suprarenal aorta with or without thrombus, 3 ϭ pronounced bulbous form of type 2 that contains thrombus, and 4 ϭ multiple aneurysms containing thrombus.
Statistical analysis was carried out using the KruskalWallis and Mann-Whitney U tests.
Results

Angiotensin Infusion Augments Atherosclerosis in ApoE؊/؊ Mice
To determine the effects of Ang II on atherosclerosis, we implanted ApoEϪ/Ϫ mice with osmotic minipumps to deliver either saline (control) or Ang II (1000 ng/kg/min) subcutaneously. Because atherosclerosis is known to progress spontaneously in ApoEϪ/Ϫ mice, we tested the effect of infusing Ang II at different ages and for varying lengths of time, corresponding to different stages in the development of atherosclerosis (Fig. 1) . The 8-to 12-week and the 4-to 16-week treatments span early stages of lesion formation (monocyte attachment and foam cell accumulation), whereas the 16-to 20-week and the 16-to 32-week treatments cover later stages involving the development of intermediate lesions and the formation of fibrous plaque. 34 In control mice, atherosclerosis at the aortic sinus increased progressively with age ( Fig. 2A) . When Ang II treatment was commenced at age 4 or 8 weeks, there were significant increases in atherosclerotic lesion area at the aortic sinus ( Fig. 2A) . However, when treatment was commenced at 16 weeks, only the 16-to 32-week treatment group showed a significant increase in atherosclerosis.
Atherosclerosis was also markedly increased in the descending aorta (Fig. 2B) , and in the aortic arch (data not shown). As observed at the aortic sinus, lesion area in the descending aorta also increased with time. However, the descending aorta was far more sensitive to the effects of Ang II, exhibiting 20-to 83-fold stimulations depending on the time and duration of treatment (Fig. 2B) . The basal rate of lesion formation in the descending aorta was slower than at the aortic sinus. Consequently, the fold stimulation in lesion area declined as the baseline lesion area increased with age (Fig. 2B) . Nonetheless, treatment with Ang II increased lesion area in the descending aorta approximately Ͼ10-fold more than at the aortic sinus. Despite differences in the relative change in lesion area associated with treatment in the descending aorta and at the aortic sinus, there were strong correlations between the lesion areas at these two sites for both control (r 2 ϭ 0.27, P Ͻ .01) and Ang II-treated (r 2 ϭ 0.43, P Ͻ .01) animals (data not shown).
The frequency and severity of aneurysms was also scored (Fig. 2B) . Across treatment groups, aneurysm frequency ranged from 71% to 100%, and the severity of aneurysm was in the 2-to 3-fold range, with the exception of the 4-to 16-week treatment group in which the severity score was Ͻ1. The severity score for the 4-to 16-week treatment group was significantly lower than the 16-to 20-week and the 16-to 32-week treatment groups (P Ͻ .05). Figure 3 shows representative aortas dissected free of connective tissue but left in situ in control and Ang II-treated mice (16-to 32-week treatment group). Lesions are evident at the branch points of the major arteries and the right subclavian artery in the control mouse. However there is extensive atherosclerosis from the aortic sinus to the iliac bifurcation in the Ang II-treated mouse. Lesion areas at the aortic sinus of these two mice were similar (C 511,238 m 2 , Ang II 694,671 m 2 ). Table 1 summarizes physiologic and biochemical data from these studies. In each group receiving Ang II, systolic BP (SBP) was, on average, 44 to 64 mm Hg higher than in the corresponding controls. In mice treated with Ang II, PRC was highly suppressed indicating a virtually complete inhibition of renal renin secretion. Total cholesterol was unaffected by Ang II except in the 4-to 16-week group, in which it was increased 43%.
Reduction of Atherosclerosis in ApoE؊/؊ Mice by Losartan
Losartan was added to the drinking water to deliver doses of 5 mg/kg/day (low dose) or 25 mg/kg/day (high dose). Table 2 summarizes physiologic and biochemical data from these studies. The lesion area was measured at the aortic sinus of individual animals in the different treatment groups (Fig. 4) . In female mice, both the low and high doses of losartan significantly reduced aortic sinus atherosclerosis 44% and 40%. In male mice, aortic sinus atherosclerosis was reduced 30% and 34%, although these differences were not statistically significant. In both males and females, total and HDL cholesterol levels were unaffected by losartan treatment, although both were higher in males as previously noted. 35 After 8 weeks of treatment with high-dose losartan, SBP was significantly lower than in controls by 19 and 23 mm Hg in male and female mice, respectively. In male mice receiving low-dose losartan, SBP was sig- nificantly lower than in controls by 13 mm Hg, whereas among similarly treated female mice, SBP appeared to rise above control levels. Time-course measurements of SBP that were taken on a subset of mice revealed that SBP in animals treated with low-dose losartan were significantly lower than in controls at 4 weeks and then began to rise (Fig. 5) .
The response to losartan treatment was further assessed by measuring the plasma renin concentration. In both male and female mice, PRC was increased approximately 4-and 20-fold by low-and high-dose losartan, respectively, although the PRC in mice treated with low-dose losartan was not significantly different from that in controls (Table 2) .
Discussion
In the present study, we showed that administration of Ang II to ApoEϪ/Ϫ mice increased lesion area both at the aortic sinus (Յ3.3-fold) and in the descending aorta (20-to 80-fold). There were also age-dependent differences in the sensitivity to Ang II at these two sites. Conversely, angiotensin receptor blockade reduced lesion area at the aortic sinus by 30% to 40%. The cardiovascular effects of both Ang II infusion and angiotensin receptor blockade were demonstrated by changes in PRC and SBP.
Our infusion studies showed that there are marked differences in the sensitivity of the aortic sinus and the descending aorta to the pro-atherogenic effects of Ang II. Although the basal rate of lesion development was greater at the aortic sinus, the stimulation by Ang II was far greater in the descending aorta. By 32 weeks age, the average increase in lesion area at the aortic sinus was 1.5-fold, and the distributions of lesion areas observed in individual mice overlapped between control and Ang II-treated mice ( Fig. 2A) . In the descending aorta, the average stimulation was Ͼ20-fold and the distributions of lesion areas observed in individual mice were completely non-overlapping between control and Ang II-treated mice (Fig. 2B) . Although the measurements taken at the aortic sinus and the descending aorta span different dimensions (measurements taken at the aortic sinus are crosssectional measurements of the area of plaque, whereas measurements taken in the descending aorta are the surface area of the lesion), it seems unlikely that this would account for the apparent difference in sensitivity to Ang II at the two sites.
Despite differences in the apparent sensitivity to the effects of Ang II, there were strong correlations between the lesion areas measured at the two sites, as described in an earlier study. 36 The smaller fold change observed at the aortic sinus is due in part to the progressive increase in lesion area that occurred in the absence of stimulation by Ang II (Fig. 2A) . However, the greater inductions observed when treatment was commenced at 8 or 12 weeks may be because early events in atherogenesis such as monocyte adhesion and their conversion to macrophages and foam cells may be more sensitive to the effects of Ang II. The strong progressive development of atherosclerosis at the aortic sinus may be due to the turbulent flow at this site compared with more distal regions of the aorta, where lesions tend to form predominantly at branch points at which laminar flow is disrupted. 37, 38 Thus, atherogenesis in the descending aorta may be suppressed by the flow conditions, making it more sensitive to the effects of Ang II, which may abrogate the protective mechanisms induced by laminar flow.
The present study also confirmed the occurrence of abdominal aortic aneurysm in Ang II-treated ApoEϪ/Ϫ mice. In each treatment group, 71% to 100% of mice had aortic aneurysms, which were, on average, grade 2 and greater except in the 4-to 16-week group, which had no aneurysms greater than grade 1. Other studies that reported a high incidence of abdominal aortic aneurysms started treatment at 24 to 44 weeks of age, lasting 4 to 8 weeks. 17, 21, 25 However, no aneurysms were reported in one study in which treatment was started at 4 to 6 weeks of age and maintained for 4 to 8 weeks. 23 In the present study, the 4-to 16-week treatment group developed the lowest frequency and lowest grade of aortic aneurysm, which may not have developed in the shorter time frame examined by Weiss et al. 23 This suggests that early exposure to Ang II may induce protective changes such as smooth-muscle cell hyperplasia and remodeling of the aortic wall. 16 Several recent studies have demonstrated regional differences in the vasculature that may account for the varying susceptibility to atherosclerosis. In ApoEϪ/Ϫ mice treated with Ang II, urokinase-type plasminogen activator (uPA) was increased 13-fold in the abdominal aorta compared with 2-fold in the aortic arch, 17 and uPA knockout mice were found to be less susceptible to aneurysm formation in response to Ang II. 25 Although aneurysm formation was accelerated in ApoEϪ/Ϫ mice, it also occurred in wild-type mice. Plasmin activation of matrix metalloproteases (MMP) has been implicated in aneurysm formation 39, 40 ; and a recent study showed that aneurysm formation can be reduced by doxycycline, which, in addition to its antibiotic effects, inhibits MMP. 41 However, there were no differences in MMP expression that could account for the distribution of aneurysms. 17 Therefore, the severity of atherosclerosis and incidence of aortic aneurysms may be affected by uPA expression, either through the proteolytic effects of plasmin on the arterial wall or though direct effects of uPA on vascular smooth muscle cells. 42 Lesion severity was associated with interleukin-6 (IL-6) production. Thus, differential expression of IL-6 may have local proatherogenic effects. Because uPA is predominantly produced by inflammatory cells, the differential expression of uPA may reflect differences in Ang II-induced IL-6 stimulation of inflammatory processes. 43, 44 Regional differences in expression of E-selectin 2 and in responses of PAI-1 and tissue plasminogen activator (t-PA) to oxidized LDL 18 may also be involved. Our blockade studies suggest that under normal conditions, the RAS contributes to lesion development in ApoE mice. In the high-dose losartan group, BP was approximately 20% lower in both males and females compared with their respective controls, and PRC was highly stimulated, demonstrating effective RAS blockade. Although, lesion area was reduced 40% in females and 30% in males, the reduction was significant only in females, possibly because of the size of the effect and the limited power due to the experimental group size.
In the low-dose losartan group, BP in females was above control levels at the end of the study (16 weeks) . In the absence of additional data, the significantly lower lesion area observed in this group might be interpreted as a BP-independent effect of losartan. However, BP in this group was significantly lower than in controls for at least part of the treatment period, and there was a reactive rise in PRC, suggesting that RAS activity was blocked. Thus, the BP-lowering and anti-atherogenic effects of RAS blockade cannot be separated, although recent studies suggest that RAS inhibition reduces expression of inflammatory molecules, 27, 28 which may reduce atherosclerosis independently of the effect on BP.
Several previous studies reported reductions in lesion areas in ApoEϪ/Ϫ mice treated RAS blockers, although there was no grouping of parameters that could distinguish between studies that found an effect and those that did not (Table 3) . Each of the studies that reported no effect of RAS blockade found significant reductions in lesion area when another drug was added 29 or when atherosclerosis was stimulated by inactivation of the eNOS gene in addition to ApoE. 30 These findings suggest that the effects of RAS blockade are relatively small and may require large experimental groups to detect.
The findings of the present study demonstrate regional and temporal differences in the sensitivity of the aorta to the effects of RAS stimulation and blockade that help to explain some of the discrepancies reported in the literature. The magnitude of lesion reduction by RAS blockade with losartan suggest that under normal conditions the RAS exerts only a relatively small stimulatory effect on lesion formation at the aortic root, where turbulent flow may stimulate proatherogenic mechanisms that cannot be inhibited by RAS blockade. Similarly, because of the high basal rate of lesion development at the aortic sinus, administration of excess Ang II had only a relatively small stimulatory effect. However, in the descending aorta, where the basal rate of lesion development is low, Ang II appeared to have a more profound stimulatory effect on atherogenesis. The timing of Ang II administration may also have important consequences on aneurysm development because of the balance of protective and detrimental mechanisms. Further studies of these processes are required to determine whether there are common pathways that can explain the basal rate of atherogenesis at each site and to elucidate their relative susceptibilities to Ang II. Understanding these mechanisms may help to develop treatments and protective approaches for human atherosclerosis and aneurysms.
FIG. 5.
Time course of blood pressure (BP) changes in mice treated with losartan. Analysis of variance showed no difference in systolic BP (SBP) of mice in this subset versus the whole group for the 8-week treatment point, suggesting that these data are representative of the whole data set. *P Ͻ .05; **P Ͻ .01; ***P Ͻ .001. BP ϭ blood pressure; other abbreviations as in Table 1 .
